Irontophoresisâ„¢: Transdermal Delivery of Iron by Iontophoresis
Irontophoresisâ„¢: Transdermal Delivery of Iron by Iontophoresis
复制标题
DOI：
10.1002/jps.21641
复制
发表时间：
2009-08-01
影响因子：
3.8
通讯作者：
Vaka, Siva Ram Kiran
中科院分区：
文献类型：
--
作者：
Murthy, S. Narasimha;Vaka, Siva Ram Kiran
铁的经皮递送可以克服胃肠副作用和与肠胃外施用相关的不适。铁的缓慢和延长的经皮递送也将避免转铁蛋白的潜在过饱和，并克服游离铁在体循环中的积累。焦磷酸铁（FPP）已被证明是安全的全身给药。FPP的被动透皮递送由于不可渗透的皮肤屏障而较差。铁离子导入法（Irontophoresis，TM）是一种用于FPP透皮给药的新方法。该技术的可预测性和可编程性在体外无毛大鼠皮肤上进行了评估。在无毛大鼠中进行6小时的铁电渗后，总血清铁浓度从182.36 +/- 39.93 μ g/dL增加到317.56 +/- 28.33 μ g/dL，转铁蛋白饱和度从44.6% 2.2%增加到60.8% 6.7%。基于铁离子透入法（TM）的铁疗法可能是治疗缺铁性贫血的相对更好的患者依从性、安全性和有效性。(C)2008 Wiley-Liss，Inc.和美国药学协会药物科学杂志98：2670-2676，2009
Transdermal delivery of iron can overcome the GI side effects and the discomfort associated with parenteral administration. Slow and prolonged transdermal delivery of iron would also avoid potential oversaturation of transferrin and overcome accumulation of free iron in the systemic circulation. Ferric pyrophosphate (FPP) has been demonstrated to be safe for systemic administration. Passive transdermal delivery of FPP is poor due to the impermeable skin barrier. Irontophoresis (TM) was developed for transdermal delivery of FPP. The predictability and programmability of the technique was assessed in vitro across the hairless rat skin. Following Irontophoresis for 6 h in hairless rats, the total serum iron concentration increased from 182.36 +/- 39.93 mu g/dL to 317.56 +/- 28.33 mu g/dL and the transferrin saturation increased from 44.6% 2.2% to 60.8% 6.7%. Irontophoresis (TM) based iron therapy could be relatively more patient compliant, safe and effective treatment for iron deficiency anemia condition. (C) 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2670-2676, 2009